drugset / Trial / NCT02705300
Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Treatment with FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) can be effective, but it has serious side effects, which may require hospitalization. The purpose of this study is to investigate whether the addition of tocotrienol can reduce the side effects to FOLFOXIRI otherwise leading to hospitalization.
Timeline
- Start
- 2016-05-06
- Primary completion
- 2019-08
- Completion
- 2024-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Calcium folinate | Unknown | 200 mg/m2 | Intravenous |
| Background | Irinotecan | Small molecule | 165 mg/m2 | Intravenous |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Background | fluorouracil | Small molecule | 3200 mg/m2 | Other |